Contraception for Women and Couples with HIV
References
Note: Full-text versions of the references in bold can be found on the CD-ROM.
1
Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDS Epidemic Update, December 2004.
Geneva, Switzerland: UNAIDS, 2004. [slide 4]
2
UNAIDS, 2004. [slide 5]
3
Central Bureau of Statistics (CBS), Kenya Ministry of Health (MOH), ORC Macro. 2004. Kenya
Demographic and Health Survey 2003. Calverton, MD: CBS, MOH, and ORC Macro, July 2004.
[slide 6]
4
UNAIDS. Report on the Global HIV/AIDS Epidemic 2002. (Geneva, Switzerland: UNAIDS,
2002)128. [slide 7]
5
Canadian International Development Agency (CIDA). HIV/AIDS in Africa. 2004. Available:
http://www.acdi-cida.gc.ca/cidaweb/webcountry.nsf/vall/2E9C2CB5BACEE92385256ECC006
B36EC?OpenDocument. [slide 7]
6
UNAIDS, 2004. [slide 8]
7
UNAIDS, 2002. [slide 9]
8
World Health Organization (WHO). Strategic Approaches to the Prevention of HIV Infection in
Infants: Report of a WHO Meeting. Morges, Switzerland, March 20-22, 2002. Available:
http://www.who.int/hiv/pub/mtct/en/StrategicApproachesE.pdf. [slide 12]
9
U.S. Agency for International Development (USAID), Bureau for Global Health. Adding Family
Planning to PMTCT Sites Increases the Benefits of PMTCT. Washington, DC: USAID, 2003.
Available: http://www.usaid.gov/our_work/global_health/
pop/publications/docs/familypmtct.html. [slide 13]
10 Population Reference Bureau. Datafinder. Indicator: Contraceptive Use Among Married Women,
Modern Methods. Available: www.prb.org. [slide 15]
11 Population Reference Bureau. Datafinder. Indicator: Unmet Need for Family Planning.
Available: www.prb.org. [slide 15]
12 Ross JA, Winfrey WL. Unmet need for contraception in the developing world and the former Soviet
Union: an updated estimate. Int Fam Plann Perspect 2002;28(3):138-43. [slide 16]
13 Saada M, Le Chenadec J, Berrebi A, et al. Pregnancy and progression to AIDS: results of the French
prospective cohorts. SEROGEST and SEROCO Study Groups. AIDS 2000;14(15):2355-60. [slide 18]
14 Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a
systematic review of the literature and meta-analysis. BJOG 1998;105(8):836-48. [slide 18]
15 Preble EA, Huber D, Piwoz EG. Family Planning and the Prevention of Mother-to-Child Transmission
of HIV: Technical and Programmatic Issues. Arlington, VA: Advance Africa, 2003. [slide 19]
16 Chen JL, Philips KA, Kanouse DE, et al. Fertility desires and intentions of HIV-positive men and
women. Fam Plann Perspect 2001;33(4):144-52. [slide 21]
August 2005
Contraception for Women and Couples with HIV
References 1
17 King R, Estey J, Allen S, et al. A family planning intervention to reduce vertical transmission of HIV
in Rwanda. AIDS 1995;9(Suppl. 1):S45-S51. [slide 22]
18 WHO. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a
Public Health Approach, 2003 Revision. Geneva, Switzerland: WHO, 2004a. [slide 26]
19 Dabis F, Leroy V, Castetbon K, et al. Preventing mother-to-child transmission of HIV-1 in Africa in
the year 2000. AIDS. 2000;14(8):1017-26. [slide 27]
20 Shelton JD, Peterson EA. The imperative for family planning in ART therapy in Africa. Lancet
2004;364(9449):1916-18. [slide 28]
21 Powderly WG. Long-term exposure to lifelong therapies. J Acquir Immune Defic Syndr 2002;29(Suppl
1):S28-S40. [slide 28]
22 WHO, 2004a. [slide 28]
23 Cates W. Use of contraception by HIV-infected women. IPPF Med Bull 2001:35(1):1-2. [slide 30]
24 Pariani S, Heer DM, Van Arsdol MD Jr. Does choice make a difference to contraceptive use?
Evidence from East Java. Stud Fam Plann 1991;22(6):384-90. [slide 31]
25 Huezo C, Malhotra U. Choice and Use-Continuation of Methods of Contraception: A Multicentre
Study. London, UK: International Planned Parenthood Federation, 1993. [slide 31]
26 WHO. Medical Eligibility Criteria for Contraceptive Use, Third Edition. Geneva, Switzerland: WHO,
2004b. [slide 40]
27 WHO, 2004b. [slide 41]
28 WHO, 2004b. [slide 42]
29 WHO, 2004b. [slide 43]
30 Hatcher RA, Trussell J, Stewart FH, et al. Contraceptive Technology, Eighteenth Revised Edition. New
York: Ardent Media, Inc., 2004. [slide 45]
31 Hatcher, 2004. [slide 46]
32 Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane
Database Syst Rev 2002;(1):CD003255. [slide 47]
33 Deschamps M-M, Pape JW, Hafner A, et al. Heterosexual transmission of HIV in Haiti. Ann Inter Med
1996;125:324-30. [slide 47]
34 Hatcher, 2004. [slide 47]
35 WHO, 2004b. [slide 48]
36 Diaz T, Schable B, Chu SY. Relationship between use of condoms and other forms of contraception
among human immunodeficiency virus-infected women. Obstet Gynecol 1995;86(2):277-82. [slide 50]
37 Leitz G, Mildvan D, McDonough M, et al. Nevirapine (VIRAMUNE, NCP) and ethinyl
estradiol/norethindrone (ORTHO-NOVUM 1/35 [21 pack] EE/NET) interaction study in HIV-1
infected women. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA,
January 30-February 2, 2000. [slide 54]
August 2005
Contraception for Women and Couples with HIV
References 2
38 Piscitelli S, Flexner C, Minor J, et al. Drug interactions in patients infected with human
immunodeficiency virus. Clin Infect Dis 1996;23(4):685-93. [slide 54]
39 WHO, 2004b. [slides 56, 57]
40 Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl
estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune
Defic Syndr 2002;29(5):471-77. [slide 56]
41 Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in
healthy female volunteers. Br J Clin Pharmacol 1998;46(2):111-116. [slide 57]
42 GlaxoSmithKline. Agenerase® (amprenavir). Prescribing information. Research Triangle Park, NC:
GlaxoSmithKline, 2004. Available: http://www.gsk.com/products/agenerase_us.htm [slide 57]
43 Lavreys L, Chohan V, Overbaugh J, et al, Hormonal contraception and risk of cervical infections
among HIV-1 seropositive Kenyan women. AIDS 2004;18(16):2179-84. [slide 59]
44 Wang CC, Kreiss JK, Reilly M. Risk of HIV infection in oral contraceptive pill users: a meta-analysis.
J Acquir Immune Defic Syndr 1999;21(1):51-58. [slide 60]
45 Wang CC, McClelland RS, Overbaugh J, et al. The effect of hormonal contraception on genital tract
shedding of HIV-1. AIDS 2004;18(2):205-9. [slide 60]
46 John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load,
genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001;183(2):206-12. [slide 60]
47 McClelland RS, Wang CC, Mandaliya K, et al. Treatment of cervicitis is associated with decreased
cervical shedding of HIV-1. AIDS 2001;15(1):105-10. [slide 61]
48 Ghys PD, Fransen K, Diallo MO, et al. The associations between cervicovaginal HIV shedding,
sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d’Ivoire.
AIDS 1997;(12):F85-93. [slide 61]
49 Lavreys L, Baeten JM, Kreiss JK, et al. Injectable contraceptive use and genital ulcer disease during
the early phase of HIV-1 infection increase plasma virus load in women. J Infect Dis 2004;189(2):30311. [slide 62]
50 Sagar M, Lavreys L, Baeten J, et al. Infection with multiple human immunodeficiency virus type 1
variants is associated with faster disease progression. J Virol 2003;77(23):12921-26. [slide 62]
51 WHO, 2004b. [slide 63]
52 Hatcher, 2004. [slide 64]
53 WHO, 2004b. [slide 64]
54 WHO, 2004b. [slide 65]
55 Mildvan, 2002. [slide 65]
56 Said S, Omar K, Koetsawang S, et al. A multicentred phase III comparative clinical trial of depotmedroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: 1. Contraceptive
efficacy and side effects. World Health Organization Task Force on Long-Acting Systemic Agents for
August 2005
Contraception for Women and Couples with HIV
References 3
Fertility Regulation. Special Programme of Research, Development and Research Training in Human
Reproduction. Contraception 1986;34(3):223-35. [slide 65]
57 WHO, 2004b. [slide 66]
58 Mildvan, 2002. [slide 66]
59 Hatcher, 2004. [slide 68]
60 Morrison CS, Sekadde-Kigondu C, Sinei SK, et al. Is the intrauterine device appropriate contraception
for HIV-1-infected women? BJOG 2001;108(8):784-90. [slide 69]
61 Richardson BA, Morrison CS, Sekadde-Kigondu C, et al. Effect of intrauterine device on cervical
shedding of HIV-1 DNA. AIDS 1999;13(15):2091-97. [slide 70]
62 WHO, 2004b. [slide 71]
63 Hatcher, 2004. [slide 72]
64 Wilkinson D, Ramjee G, Tholandi M, et al. Nonoxynol-9 for preventing vaginal acquisition of HIV
infection by women from men (Cochrane Review). Cochrane Database Syst Rev 2002;(4):CD003936.
[slide 72]
65 Wilkinson D, Ramjee G, Tholandi M, et al. Nonoxynol-9 for preventing vaginal acquisition of sexually
transmitted infections by women from men (Cochrane Review). Cochrane Database Syst Rev
2002;(4):CD003939. [slide 72]
66 WHO, Contraceptive Research and Development Project (CONRAD). Safety of Nonoxynol-9 When
Used for Contraception: Report from WHO/CONRAD Technical Consultation, October 2001. Geneva,
Switzerland: WHO and CONRAD, 2002. Available: http://www.who.int/reproductive-health/rtis/
nonoxynol9.html. [slide 72]
67 Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on
HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002;360(9338):97177. [slide 72]
68 Hatcher, 2004. [slide 73]
69 Moench TR, Chipato T, Padian NS. Preventing disease by protecting the cervix: the unexplored
promise of internal vaginal barrier devices. AIDS 2001;15(13):1595-1602. [slide 73]
70 Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal
mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000;74(13):
6087-95. [slide 73]
71 WHO, 2004b. [slide 74]
72 Gottlieb G, Nickle D, Jensen M, et al. HIV-1 superinfection in a rapid disease progressor: rapid
replacement of the initial strain with the superinfecting virus by natural selection. Eleventh Conference
on Retroviruses and Opportunistic Infections, San Francisco, CA, February 8-11, 2004. [slide 74]
73 Hatcher, 2004. [slide 75]
74 WHO, 2004b. [slide 76]
75 Hatcher, 2004. [slide 77]
August 2005
Contraception for Women and Couples with HIV
References 4
76 WHO, 2004b. [slide 78]
77 Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission
of HIV-1: a randomized clinical trial. JAMA 2000;283(9):1167-74. [slide 78]
78 De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in
resource-poor countries: translating research into policy and practice. JAMA 2000;283(9):1175-82.
[slide 78]
79 Hatcher, 2004. [slide 79]
80 WHO, 2004b. [slide 80]
81 Chervenak FA, McCullough LB. Common ethical dilemmas encountered in the management of HIVinfected women and newborns. Clin Obstet Gynecol 1996;39(2):411-19. [slide 84]
82 McIntyre J. HIV in Pregnancy: A Review (Geneva, Switzerland: World Health Organization/UNAIDS,
1999)7. [slide 85]
83 Bessinger R, Clark R, Kissinger P, et al. Pregnancy is not associated with the progression of HIV
disease in women attending an HIV outpatient program. Am J Epidemiol 1998;147(5):434-40. [slide
85]
84 Immunological markers in HIV-infected pregnant women. The European Collaborative Study and the
Swiss HIV Pregnancy Cohort. AIDS 1997;11(15):1859-65. [slide 85]
85 Vimercati A, Greco P, Lopalco PL, et al. Immunological markers in HIV-infected pregnant and nonpregnant women. Eur J Obstet Gynecol Reprod Biol 2000;90(1):37-41. [slide 85]
86 Working Group on Mother-to-Infant Transmission of HIV. Rates of mother-to-infant transmission of
HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. J Acquir Immune Defic Syndr
Hum Retrovirol 1995;8(5):506-10. [slide 85]
87 WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality.
Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed
countries: a pooled analysis. Lancet 2000;355(9202):451-55. [slide 86]
August 2005
Contraception for Women and Couples with HIV
References 5